ESMO: Novartis links prostate cancer drug to improved pain, quality of life as regulatory filings near

Novartis is building the case for its radioligand therapy. With positive phase 3 primary endpoint data in the bag, Novartis arrived at the European Society of Medical Oncology Congress 2021 armed with evidence of the therapy’s effect on quality of life and pain.

Earlier this year, Novartis revealed the phase 3 trial linked 177Lu-PSMA-617 to a four-month median improvement in overall survival. Having shown the drug candidate improves survival in patients with metastatic castration-resistant prostate cancer, Novartis began digging into secondary endpoints that could shed light on the day-to-day effects of the treatment.